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The Blood Pressure Lowering Treatment Trialists’ 
(BPLTTC) analysis of outcomes of antihypertensive 
treatment in older and younger adults Whether 
older and younger persons derive similar bene‑
fit from antihypertensive treatment and wheth‑
er treatment choices should be tailored to the age 
of the patient are unresolved issues about which 
there is a paucity of evidence. The BPLTTC has 
attempted to address this deficiency by compar‑
ing the relative reductions in blood pressure (BP) 
and cardiovascular disease risk achieved with 
different BP lowering regimens in younger and 
older adults.1 The Trialists compared the pro‑
portionate risk reductions achieved with differ‑
ent classes of antihypertensive drugs in younger 
(<65 years) and older (≥65 years) adults enrolled 
in randomized controlled trials in a meta‑analy‑
sis that included 31 trials with 190,606 partici‑
pants. The treatment regimens that were com‑
pared were those previously reported in the Trial‑
ists’ second main cycle of overviews: angiotensin‑
‑converting enzyme inhibitors (ACEI) vs. placebo, 
calcium channel blocker (CCB) vs. placebo, more 
intensive vs. less intensive BP lowering regimens, 
angiotensin receptor blockers (ARB) vs. control 
regimen, ACEI vs. diuretics/β‑blockers (BB), CCB 
vs. diuretics/BBs, and ACEI vs. CCBs.2 Additional 
comparisons, particularly relevant to some cur‑
rent treatment guidelines, included ACEI or CCB 
vs. BBs and ACEI or CCB vs. diuretics in the older 
and younger age groups. The age cut‑offs speci‑
fied above were chosen because most participat‑
ing trials used the same categories in their own 
subgroup analyses.
There was no significant difference between 
age groups in the effects of lowering BP and no 
age‑dependent difference between the effects 
of the drug classes on major cardiovascular events. 
Further, there was no significant interaction be‑
tween age and the effects of treatment when age 
was fitted as a continuous variable and overall ef‑
fects were estimated across trials. Meta‑regres‑
sion analysis of the effects of BP lowering in the 2 
age groups also showed no difference between 
groups in the risk reduction achieved/unit re‑
duction in BP for the primary outcome of ma‑
jor cardiovascular events or for any secondary 
outcome.
The Trialists concluded that BP reduction pro‑
duces benefit in both younger (<65 years) and 
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ABsTRACT
Whether older and younger persons derive similar benefit from antihypertensive treatment and whether 
treatment choices should be tailored to the age of the patient are unresolved issues about which there 
is a paucity of evidence. The Blood Pressure Lowering Treatment Trialists' Collaboration has attempted 
to address this deficiency in a meta‑analysis that included 31 trials with 190,606 participants. They 
compared the proportionate risk reductions achieved with different classes of antihypertensive drugs 
in younger (<65 years) and older (>65 years) adults. They reported that there was no clear evidence 
to support recommendations for particular antihypertensive drug classes in older or younger adults. 
In this paper we discussed the Trialists’ paper and its limitations and strenghts, current guidelines 
recommendations, and the major conclusions that are important for clinicians.
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Of note, none of these studies had cardiovascu‑
lar disease and mortality outcomes.
Unlike most older guidelines, the British and 
Canadian guidelines do not recommend use of BBs 
as initial therapy for hypertension except in spe‑
cial cases, e.g. in younger people, those with in‑
creased sympathetic drive or intolerance to ACEI 
or ARB, and women of childbearing potential.3‑5 
The recommendation that BBs not be used as first 
line treatment in older patients was based on evi‑
dence from randomized controlled trials that tra‑
ditional BBs, particularly atenolol, are ineffective 
in lowering BP and preventing cardiovascular dis‑
ease outcomes in this age group.13‑17 The British 
guidelines recommend that BBs generally be re‑
served as 4th line therapy for older patients who 
fail to achieve BP control on a triple combina‑
tion of ACEI/ARB + CCB + thiazide‑type diuretic 
and for those with a “compelling indication” for 
BB use, e.g. coronary artery disease. The ratio‑
nale for choosing BBs for younger hypertensive 
patients includes the observation that younger 
persons in the early stages of hypertension fre‑
quently have a hyperdynamic circulation asso‑
ciated with increased sympathetic nervous sys‑
tem activity, as well as RAAS activation.18 Sym‑
patholytic interventions, including BB therapy, 
would be expected to be effective in lowering BP 
in such individuals.
UsA and European guidelines do not recommend 
stratifying antihypertensive treatment by patient’s 
age Unlike the British and Canadian guidelines, 
and consistent with the Trialists’ meta‑analysis, 
the Seventh Report of the Joint National Com‑
mittee on prevention, detection, evaluation, 
and treatment of high BP and the Task Force 
for the Management of Arterial Hypertension 
of the European Society of Hypertension (ESH) 
and of the European Society of Cardiology (ESC) 
do not recommend that antihypertensive treat‑
ment choices be based on the patient’s age.19,20 
The ESH/ESC guidelines support the concepts 
that the main benefits of antihypertensive treat‑
ment are due to BP lowering per se and are large‑
ly independent of the drugs employed and that 
all classes of antihypertensive drugs that have 
been shown to effectively lower BP and reduce 
cardiovascular outcomes, i.e. thiazide and thiaz‑
ide‑like diuretics, BBs, CCBs, ACEI and ARB, are 
suitable for the initiation and maintenance of an‑
tihypertensive therapy. While these guidelines 
acknowledge that individual patient character‑
istics, e.g. the presence of subclinical target or‑
gan damage, underlying cardiovascular disease or 
other important comorbidities, may dictate spe‑
cific treatment choices, they do not identify age 
as such a determinant.
Antihypertensive treatment in the younger patient… 
What clinical trials don’t tell us Age is, howev‑
er, an important consideration when calculat‑
ing the benefit and cost‑effectiveness of anti‑
hypertensive treatment. In younger, low‑risk 
older (>65 years) adults, with no strong evidence 
that protection against major vascular events af‑
forded by different drug classes varies substan‑
tially with age. Thus, they reported that there 
was no clear evidence to support recommenda‑
tions for particular antihypertensive drug class‑
es in older or younger adults, as included in some 
current treatment guidelines.3‑5
British and Canadian guidelines recommend modi-
fying antihypertensive treatment according to pa-
tient’s age The Trialists’ analysis does not sup‑
port the recommendations of the British Joint 
Societies’ guidelines on prevention of cardiovas‑
cular disease that hypertensive patients aged 
≥55 should start treatment with either a CCB or 
a thiazide‑type diuretic and that an ACEI or ARB 
is preferred in those <55 years of age.3,4 These 
recommendations are based on evidence from 
renin‑profiling studies that younger people (<55 
years) and Caucasians tend to have higher renin 
levels than older people (≥55 years) and Blacks 
of any age.6‑8 Therefore, the guideline writers con‑
cluded that renin‑angiotensin‑aldosterone sys‑
tem (RAAS) blockade with ACEI, or ARB treat‑
ment would be more effective as initial BP lower‑
ing therapy for younger Caucasian patients than 
for older Caucasian or Black patients of any age, 
as these drugs decrease BP in part by suppress‑
ing the RAAS.
This line of reasoning suggests that older pa‑
tients and Black patients of any age, who tend 
to be volume expanded and to have low renin lev‑
els, should be more responsive to other antihy‑
pertensive drug classes, i.e. diuretics and CCBs. 
In part, these conclusions are supported by clin‑
ical trial data. For example, 3 cooperative studies 
by the Department of Veterans Affairs in the USA 
showed that thiazide diuretics were more effec‑
tive in older patients than in younger ones and, 
in particular, had a greater effect on systolic BP 
in older patients.9 The Department of Veterans Af‑
fairs Single‑drug Therapy of Hypertension Study, 
which compared the BP effects of representa‑
tives of 6 antihypertensive drug classes to placebo, 
showed that among male veterans, age and race 
had an important effect on the response to sin‑
gle‑drug therapy for hypertension.10 CCB treat‑
ment lowered BP more effectively than other drug 
classes in older veterans, particularly in Blacks, 
while ACEI treatment was most effective and di‑
uretic treatment least effective in younger Cau‑
casians. Interestingly, age and race were more 
robust predictors of therapeutic response than 
baseline renin profile in this study.11 In con‑
trast, the Treatment of Mild Hypertension Study 
(TOMHS), which compared the BP lowering ef‑
fects of low doses of representatives of 5 leading 
antihypertensive drug classes to placebo, found 
no differences between active treatments.12 This is 
likely due to the homogeneous study population 
of TOMHS, which included only younger, main‑
ly Caucasian patients with stage 1 hypertension. 
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of lowering BP to more aggressive goals in this 
patient population.
Additional limitations of the Trialists’ meta‑
‑analysis may have blunted their ability to de‑
tect real differences in treatment effects be‑
tween age groups. These include differences 
in baseline BP, gender distribution and comor‑
bidities between age groups; the short duration 
of follow ‑up in most trials, which makes it im‑
possible to evaluate possible longer ‑term differ‑
ential effects of treatment, and incomplete ad‑
herence to randomized treatments and exten‑
sive use of add‑on therapies. Use of a compos‑
ite outcome of major cardiovascular events as 
the basis for primary analyses is also problem‑
atic in that the type of cardiovascular event var‑
ies between age groups, stroke (which is more 
strongly affected by BP lowering) being more 
common in the older age group. This would tend 
to inflate the magnitude of the proportional re‑
duction in events seen in the older compared 
to the younger group.
sUMMARY  Despite these limitations, the very 
large number of patients included in the analy‑
ses, the care with which the data were collected 
and analyzed and the consistency of results ob‑
tained using different statistical techniques pro‑
vide reassurance that the findings of the Trialists’ 
analysis are real. The major conclusions that are 
important for clinicians are:
 1) BP reduction produces similar proportional re‑
ductions in risks of vascular events in young‑
er (<65 years) and older (≥65 years) adults, 
with the caveat that there is a paucity of data 
for those <50 years
 2) absolute benefits of treatment are likely larg‑
er among older individuals because of their 
high absolute risk
 3) there is no clear evidence to support recom‑
mendations for particular drug classes in old‑
er vs. younger adults.
The final conclusion should perhaps be tem‑
pered by the caveat that outcome data are very 
limited for younger (<50 years) hypertensive pa‑
tients, and use of surrogate outcomes, including 
BP reduction, in making clinical decisions is con‑
troversial. Further, the question of which anti‑
hypertensive drug class is preferred for initial 
treatment of hypertension in either age group 
has diminished in importance as we have learned 
that most patients will require a combination 
of at least two drugs to achieve the accepted BP 
goals. For example, in the Antihypertensive and 
Lipid Lowering treatment to prevent Heart At‑
tack Trial (ALLHAT), 62.5% of patients needed 
≥2 drugs after 5 years of follow‑up to reach a goal 
of <140/90 mmHg.24,25
The question of which combinations are bet‑
ter is beginning to be asked in randomized con‑
trolled trials. The first major trial to test the out‑
comes of starting with combination therapy, 
the Avoiding Cardiovascular Events through 
Combination Therapy in Patients Living with 
hypertensive patients, the benefit of treatment 
appears small when calculated over a treatment 
period of 5 years, as in most randomized con‑
trolled outcome trials. Therefore, these trials 
exclude younger patients. The short term goal 
in these patients is not to prevent a morbid or 
mortal cardiovascular event, which is unlikely, 
but to prevent the acceleration of hypertension 
and the onset and/or progression of subclinical 
target organ damage that will eventually result 
in overt cardiovascular disease and death.21,22 
Thus, while early institution of antihypertensive 
treatment in younger individuals may be high‑
ly beneficial, the benefit is deferred and is diffi‑
cult to assess by usual methods. As pointed out 
by Zanchetti, in younger hypertensive persons, 
actuarial data from life insurance companies or 
other sources may provide a better assessment 
of treatment benefit than trial data.22 In addi‑
tion, development of more rigorous and validat‑
ed methods of assessing the prognostic signifi‑
cance of biomarkers and subclinical target organ 
damage may be helpful in this regard.
Limitations of the Trialists’ meta analysis The Tri‑
alists’s meta‑analysis suffers from the limitations 
of its component studies, including the failure 
to provide information about treatment effects 
in younger hypertensive patients. Most of the tri‑
als included in the analysis excluded participants 
<55 years in order to assure sufficiently high 
event rates with reasonable sample sizes. Thus, 
the mean age of participants in the younger and 
older groups was 57 and 72 years, respectively, 
and the 15 year age difference between the groups 
may not have been large enough to detect a real 
difference in the effectiveness of BP lowering 
between age groups. Similarly, because most pa‑
tients in the trials fell within a fairly limited age 
range, the analysis was not informative regard‑
ing the outcome effects of antihypertensive treat‑
ment in the very elderly.
The benefits of reducing BP in very elderly 
patients have been established by the positive 
findings of the recently published HYpertension 
in the Very Elderly Trial (HYVET).23 HYVET en‑
rolled 3845 hypertensives, aged ≥80 years, with 
a baseline systolic BP >160 mmHg and no demen‑
tia or serious illness and randomized them to ei‑
ther active treatment with indapamide ±the ACEI 
perindopril or placebo. Active treatment result‑
ed in a mean BP reduction of 15/6 mmHg and 
statistically significant reductions in total mor‑
tality (−21%), fatal stroke (−39%), heart failure 
(−64%) and the combined endpoint of cardiovas‑
cular events (−34%) compared to placebo after 2 
years. Benefit was seen early and the treatment 
was well tolerated. The authors caution that these 
results cannot be extrapolated to the entire elder‑
ly population, as patients with dementia and frail‑
ty were excluded. Further, the treatment goal was 
a systolic BP of 150 mmHg, and results of the tri‑
al do not allow us to weigh the risks and benefits 
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Systolic Hypertension (ACCOMPLISH) trial, 
found very high (nearly 80%) BP control rates 
in both treatment arms.26‑28 Preliminary results 
of ACCOMPLISH have revealed a major 20% re‑
duction in cardiovascular events with a CCB–ACEI 
combination compared to a diuretic–ACEI com‑
bination in the absence of major BP differences 
between arms. Further study is needed to iden‑
tify which drug combinations are most effective 
and safest in different patient groups, includ‑
ing older and younger persons. It is important 
to remember that safety can become an overrid‑
ing consideration in some patients, e.g. women 
of childbearoing potential, in whom RAAS block‑
ers are contraindicated because of the risk of fe‑
tal developmental abnormalities.
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